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Vesicular glutamate release from central axons
contributes to myelin damage
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The axon myelin sheath is prone to injury associated with N-methyl-D-aspartate (NMDA)-
type glutamate receptor activation but the source of glutamate in this context is unknown.
Myelin damage results in permanent action potential loss and severe functional deﬁcit in the
white matter of the CNS, for example in ischemic stroke. Here, we show that in rats and mice,
ischemic conditions trigger activation of myelinic NMDA receptors incorporating GluN2C/D
subunits following release of axonal vesicular glutamate into the peri-axonal space under the
myelin sheath. Glial sources of glutamate such as reverse transport did not contribute sig-
niﬁcantly to this phenomenon. We demonstrate selective myelin uptake and retention of a
GluN2C/D NMDA receptor negative allosteric modulator that shields myelin from ischemic
injury. The ﬁndings potentially support a rational approach toward a low-impact prophylactic
therapy to protect patients at risk of stroke and other forms of excitotoxic injury.
DOI: 10.1038/s41467-018-03427-1 OPEN
1 University of Plymouth, Plymouth PL6 8BY, UK. 2 University of Malta, Msida MSF 2080, Malta. Correspondence and requests for materials should be
addressed to R.F. (email: Robert.fern@plymouth.ac.uk)
NATURE COMMUNICATIONS |  (2018) 9:1032 | DOI: 10.1038/s41467-018-03427-1 | www.nature.com/naturecommunications 1
12
34
56
78
9
0
()
:,;
Myelin is an insulating, low-capacitance layer that wrapsaround the axon cylinder and is essential for fast actionpotential conduction. Myelin injury is fundamental to
the functional loss the white matter of the CNS experiences in
multiple sclerosis, trauma, and stroke1–3. Surprisingly, N-methyl-
D-aspartate (NMDA)-type glutamate receptor (GluR) expression
levels in myelin are comparable to those at neuronal synapses4–6,
are found in humans6, and confer an elevated injury sensitivity
under conditions of high extracellular glutamate4,5,7,8. The
established view is that the glutamate release responsible for over-
activation of myelinic NMDA GluRs under pathological condi-
tions occurs via reverse glutamate uptake9–11. However, extra-
cellular glutamate concentration has not previously been directly
recorded within white matter while recent reports highlight
vesicular release as an alternative potential source of white matter
glutamate12–14. Under ischemic conditions, axonal vesicular
glutamate release will empty directly onto the myelin sheath and
may be trapped within the peri-axonal space between the axo-
lemma and the internal myelin surface. The spatial characteristics
of axon vesicular glutamate release may therefore be particularly
relevant to myelin pathology. Myelinic NMDA receptors incor-
porate GluN2 C and D subunits and should be sensitive to
selective negative allosteric modulators. GluN2C/D-containing
NMDA receptors are generally extra-synaptic while negative
allosteric modulators exhibit use-dependent properties. These
features suggest that a putative myelinic NMDA receptor/axo-
vesicular glutamate pathway may be particularly amenable to
therapeutic intervention with clinical potential.
Results
Vesicular glutamate release in white matter is primarily axonal.
Vesicular docking in white matter was examined via live two-
photon confocal imaging of ﬂuorescent FM4-6415 in corpus
callosum axons of adult Thy-1/YFP mice. Low magniﬁcation
images revealed extensive axonal FM4-64 loading, with individual
axons reliably imaged at higher magniﬁcation (Fig. 1a–d). A
similar approach using GFAP-GFP mice revealed ﬁbrous white
matter astrocytes with low levels of FM4-64 staining compared to
neighboring axons (Fig. 1e, f; Supplementary Fig. 1d, e). FM4-64
de-staining (vesicular docking) was evoked by 50 mMK+ perfu-
sion, producing rapid docking in corpus callosum axons (sig-
niﬁcant within 60 s), but not in astrocytes (Fig. 1g). The [K+]
used to evoke this response is comparable to that recorded during
brain ischemia16, and produced axon depolarization sufﬁcient to
reversibly block excitability (Supplementary Fig. 1a–c). To our
knowledge, this is the ﬁrst direct comparison of vesicular fusion
within different cellular components in white matter, and it
reveals extensive fusion in axons compared to their companion
astrocytes and is consistent with earlier observation of vesicular
release from axons15. We have shown previously that YFP(+)
axons in this model are myelinated17 and the diameter of YFP(+)
axon in the current study had a range considerably higher than
the upper limit for non-myelinated axons in mouse corpus cal-
losum18 (Supplementary Fig. 1f). As there was no evidence of
localized de-staining along YFP(+) axons imaged in long-section
(L-S), the majority of vesicular fusion in these axons must occur
under the myelin sheath and empty into the periaxonal space.
This mechanism was also triggered by ischemic conditions where
signiﬁcant axonal release was found after 15 min (Fig. 1h).
The glutamate concentration in the extracellular space
([glutamate]e) increased by 13.0 ± 3.6 μM during perfusion with
50 mM [K+] (Fig. 1i–k), a rise that was not inhibited by
glutamate transport inhibition (200 μM TBOA) but was sig-
niﬁcantly reduced by inhibition of vesicular glutamate loading
(50 nM baﬁlomycin; Fig. 1i–k). Note, axonal glutamate
transporters are localized primarily to the node of Ranvier rather
than the internodal region19 and TBOA is likely to access axonal
transport sites relatively quickly. In the adult corpus callosum,
TBOA evoked a 1.3 ± 0.4 µM peak increase in resting [glutamate]e
indicating ongoing glutamate regulation in white matter via
glutamate transport under physiological conditions (Supplemen-
tary Fig. 2).
FM4-64 axon imaging reported uniform vesicle fusion along
axons with no focal sites of fusion that might indicate local
glutamate release at nodes of Ranvier; vesicular glutamate release
must therefore empty largely into the periaxonal space under the
myelin sheath which covers 99% of the axon cylinder. Consistent
with this, an established DiOC6(3)/X-rhod-1 confocal imaging
protocol8 reported elevated [Ca2+]i in the cytoplasmic
compartment of the myelin sheath following depolarization with
50 mMK+ (Fig. 2a, b). Myelin X-rhod-1 loading is largely
peri-axonal5,8 and the myelinic K+-evoked [Ca2+]i rise was
prevented by pre-incubation with baﬁlomycin, indicating myelin
calcium inﬂux following vesicular glutamate release from axons.
Ultrastructural analysis of long-section (L-S) rodent optic nerve
(RON) axons revealed regions of 20–50 nm axoplasmic vesicle
clusters within the internodal zones (Fig. 2c arrows); vesicles were
not clustered within nodal regions and were not observed in glial
processes aligned adjacent to myelinated axons. RONs exposed to
30 min of oxygen–glucose deprivation (OGD) prior to ﬁxation
contained signiﬁcantly fewer internodal axoplasmic vesicles
(Fig. 2d, f, g), and in these nerves the vesicles were found at the
sub-myelinic axolemma occasionally caught in the act of
membrane docking/fusion (Fig. 2d, e). As in control nerves, such
vesicles were absent from glial processes neighboring the myelin
(e.g., Fig. 2d). The ultrastructural and X-rhod-1 imaging data
conﬁrm internodal axoplasmic vesicle-axolemma docking, which
will release glutamate into the periaxonal space beneath the
myelin sheath and may lead to early focal myelin damage. Axon
cylinders were largely unaffected after 30 min of OGD and
retained normal microtubules, a feature of healthy axons (Fig. 2d,
white arrows). Early signs of myelin damage were evident at sites
where axoplasmic vesicles were present and included localized
splitting and bubbling of the lamina (Fig. 2d, e*).
White matter ischemic glutamate release is primarily vesicular.
The corpus callosum sits adjacent to gray mater structures such as
the cortex (Fig. 1a) that have extensive glutamatergic input. To
avoid the potential for spillover from gray matter synapses, we
examined [glutamate]e in isolated RON, a white matter structure
with no neuronal synapses or neighboring gray matter. Resting
[glutamate]e was 8.9 ± 1.4 μM in adult rat RON, higher than the
1.3–4.5 μM range recorded in other white matter preparations
(Supplementary Fig. 2a). Glutamate biosensor electrodes were
found to be anoxia-sensitive (Supplementary Fig. 3) and ischemia
was therefore modeled using combined aglycemia/oxidative
phosphorylation block, producing a 22.4–27.5 μM glutamate rise
(Fig. 3a, b). Block of glutamate transport (TBOA or zero-Na+)
did not signiﬁcantly reduce the ischemic glutamate increase, but
release was both Ca2+- and voltage-gated Ca2+ channel (100 μM
diltiazem)-dependent as predicted for vesicular release (Fig. 3a,
b). Recording from adult RON required a long period of stabi-
lization following sensor insertion (Supplementary Fig. 4c), and
ischemic [glutamate]e was more extensively examined in juvenile
rat RON, which stabilized more quickly. At this age, ischemia
evoked a 5.6 ± 0.8 μM [glutamate]e rise that was not signiﬁcantly
affected by block of glutamate transport (TBOA, or zero-Na+),
swelling-mediated glutamate release (5 mM furosemide),
cysteine-glutamate antiport (250 μM SAS), P2X7-, pannexin- and
connexin-channels (100 μM CBX), or swelling-operated channels
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(100 μM NPPB) (Fig. 3c, d). Glutamate release was
Ca2+-dependent and was signiﬁcantly reduced by blockers of
vesicular glutamate release (50 nM baﬁlomycin or 500 nM rose
bengal; Fig. 3e, f), conﬁrming the signiﬁcance of vesicular release
to ischemic [glutamate]e elevation in white matter.
NMDA receptors mediate acute myelin injury during ischemia.
Drug penetration into the peri-axonal space is known to be slow.
For example, diffusion from the node of Ranvier into the peri-
nodal space that is contiguous with the periaxonal space takes
several hours20. Drugs may also access the peri-axonal space
directly through the myelin sheath if they are lipid soluble, e.g. the
NMDA blocker MK-801 that associates/dissociates with synaptic
lipid membrane with a time constant (τ) of ~4 min21, indicating
τ= 56 min for penetration through the sheath of a typical mature
RON axon. Prior studies have shown that short periods of
NMDA-receptor block fail to protect adult white matter from
ischemic injury11,22, and we also found no protection following a
20 min pre-treatment period with MK-801 (Fig. 4b). However,
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Fig. 1 Axons are the principle site of white matter vesicular fusion. a Thy-1-YFP expression in adult coronal section (box: corpus callosum). b, c YFP(+)
corpus callosum axons (b) and FM4-64 vesicles (c overlaid red). d Single axons (overlaid at higher gain in the box). e, f Corpus callosum astrocyte (e) in
adult GFAP-GFP mouse and FM4-64 staining (f overlaid red). g K+-evoked FM4-64 de-staining in whole corpus callosum, axons, and astrocytes. h Corpus
callosum axon FM4-64 de-staining in aCSF and during ischemia. i K+-evoked [glutamate]e release is not inhibited by TBOA. j Both the ﬁrst (top) and
second (bottom) 50mMK+-evoked glutamate rise is reduced by baﬁlomycin (50 nM, red trace). k Data summary shown on the bottom. Scale= 1 mm (a),
10 μm (b, d, f). Stars indicate the ﬁrst mean to reach signiﬁcance. Grouped analysis ANOVA; correct for multiple comparisons using the Holm−Šídák
method. P values: g top *0.016, **0.001, ***0.0000; g middle *0.038, **0.002, ***0.0004; h *0.021, **0.009, ***0.0013. Unpaired t-test P values: k Peak 1
ns 0.1119; Peak 2 *0.048
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MK-801 protection increased with pre-treatment time with
maximal protection of >400% after 120 min pre-treatment
(Fig. 4a, b). Myelinic NMDA GluRs contain the GluN2C/D
subunit4,5,7 and we tested 120 min pre-treatment with the
GluN2C/D-speciﬁc antagonists PPDA (50 μM) and QNZ-46 (50
μM)23, which also signiﬁcantly increased recovery from ischemia
(Fig. 4c). TRPA1 receptor block (10 μM A967076) has recently
been shown to be protective against ischemic injury in oligo-
dendrocyte processes and myelin sheaths24, but did not provide
functional white matter protection in our model of acute ischemic
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Fig. 2 Vesicular release under the myelin. a Myelin loaded with DiOC6 (green) and the Ca2+-indicator X-rhod-1 (red) in adult mouse RON. Note the
loading into myelin proﬁles (e.g., arrow). b Top: X-rhod-1 intensity (relative to initial mean) is elevated following depolarization with 50mMK+ (black line)
consistent with activation of NMDA receptors in the myelin, an effect blocked by pre-treatment with the vesicular loading blocker baﬁlomycin (red line). b
Bottom: data summary. Asterisks on the error bars indicate P= 0.0000 signiﬁcance vs., the initial ﬂuorescence mean; on the bar they indicate P=
0.0000 signiﬁcance vs., the two conditions. n= 5 mice in each protocol, 1–3 slices/mouse, ANOVA with Holm−Šídák post test. Bar= 8 μm. c 20–50 nm
vesicles are present in clusters in the sub-myelinic axoplasm (e.g., arrows) (Ax= axons; Ast= astrocyte process containing glial ﬁlaments; bar= 1 μm). d
Sub-myelinic vesicles are less common in RONs ﬁxed after 30min of OGD and can be seen juxtaposed on the axolemma (black arrow). White boxed area
shown at higher magniﬁcation above. Note the absence of vesicles in the astrocyte process identiﬁed by the presence of glial ﬁlaments (Gf), and the
retention of microtubules in myelinated axons (white arrows). Bar= 1 μm. e A single vesicle (black arrow) docked with the axolemma (arrow heads)
beneath the myelin following OGD. Note the presence of focal myelin injuries in both (d) and (e) (white asterisks). Bar= 500 nm. f, g The distribution of
vesicle clusters in axon proﬁles by number of vesicles in control and 30min OGD RONs (per ﬁeld of view). Note the large number of axons with zero
vesicles following OGD (scales differ). h, i Focal myelin injury scores are shifted to higher values in myelin regions adjacent to axoplasmic vesicles post
OGD compared to control RONs
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injury (Fig. 4c). Previous studies of oligodendrocyte injury have
often relied on live imaging of the cells cytoplasmic domain5,7,24.
Simultaneous live imaging of the myelinic and cytoplasmic
domains of oligodendrocytes revealed that they are largely dis-
tinct (Fig. 4d) and that morphological and structural changes in
oligodendrocyte processes imaged via ﬂuorescence label expres-
sion do not reﬂect myelin pathology. Dual domain imaging
during ischemia showed the myelin decompaction predicted by
prior ultrastructural studies (Fig. 4e, f), with ongoing disruption
of cell processes/somata swelling. Myelin thickness increased
from 0.67 μm ±0.02 to 0.90 μm ±0.07 after 60 min ischemia +60
min recovery, an effect that was prevented by 120 min pre-
treatment with QNZ-46 (Fig. 4e, f). Ultrastructural analysis
revealed extensive myelin decompaction and bubbling following
the standard OGD protocol, in addition to disruption of glial
processes and soma (Fig. 5a–c). Bubbling of the inner myelin
layer was particularly evident following OGD (Fig. 5c) and
involved regions where the inner myelin layer detached from the
remaining compact myelin and formed a series of bubbles.
Myelin bubbling was accompanied by a reduction in the number
of myelin layers (Fig. 5c small arrows). Axon cylinders in these
regions (Fig. 3c Ax) often retained microtubule proﬁles and a
clearly contiguous axolemma separating the cylinder from the
myelin bubbles. The myelin protection recently reported follow-
ing TRPA1 block did not extend to structures deﬁned as axo-
plasmic vesicles24, which appear to have similar features to the
myelin bubbles we here identify under the remaining compact
myelin sheath. 120 min pre-treatment with QNZ-46 almost
entirely prevented these structural changes (Fig. 5d–f). Quanti-
tative analysis of myelin decompaction via G-ratio analysis of
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Fig. 3 White matter ischemic glutamate release is primarily vesicular. a Ischemia-evoked [glutamate]e elevation in adult rat RON is Na+-independent/
TBOA-insensitive. b The ischemic-[glutamate]e rise is Ca2+-dependent (ANOVA with Holm−Šídák post test: P= 0.012) and diltiazem-sensitive (P=
0.010). c, d In juvenile rat RON, the ischemic [glutamate]e elevation (P= 0.001 vs., control aCSF) is Ca2+-dependent (P= 0.009 vs., ischemia)/Na
+-independent and resistant to inhibitors of non-vesicular glutamate release pathways. e, f Ischemic-[glutamate]e elevation in juvenile RON is signiﬁcantly
inhibited by blockers of vesicular glutamate loading baﬁlomycin (P= 0.004); rose bengal (P= 0.013) and combined baﬁlomycin+ TBOA (P= 0.004)
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axon cross-section (X-S) conﬁrmed the myelin protecting prop-
erties of the drug (Fig. 5g–k). GluR-mediated myelin loss during
OGD was conﬁrmed in the RON by diminished intensity of the
established myelin stain FluoroMyelin Red (FM) (Fig. 5l).
QNZ-46 is a 4-oxo-3(4H)quinazolinyl derivative containing
the trans-stilbene pharmacophore23 and has the lipophilicity
common to ﬂuorescent myelin stains25, although with reduced
aromaticity in the A ring (Supplementary Fig. 5a). The structure
also contains the quinazolinone backbone known to exhibit
strong ﬂuorescence26 and the drug therefore has the structural
components of a ﬂuorescent myelin stain. QNZ-46 had a peak
emission at 450 nm in a lipid environment (Supplementary
Fig. 5b), allowing drug uptake to be monitored in real time. QNZ-
46 loaded into adult rat RON from the bath over 120 min and was
retained following wash-out (Fig. 6a). After 120 min of bath
loading into brain slices, vital QNZ-46 ﬂuorescence was localized
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Fig. 4Myelin injury is NMDA-receptor-mediated. a CAP recordings from adult rat RON showing elevated functional recovery from ischemia following 120
min MK-801 pre-treatment. b Ischemia-evoked loss and recovery of function following different periods of MK-801 pre-treatment (insert: data summary).
ANOVA with Holm−Šídák post test. P values: 90min **0.002; 120min ***0.0001; 165 min ***0.0000. c 120min pre-treatment with selective NMDA
receptor GluN2C/D blockers QNZ-46 (P= 0.0013) or PPDA (P= 0.0009), or the TRPA1 blocker A967076. d Oligodendrocyte cytoplasmic domain (PLP-
GFP mouse, arrows) is distinct from the myelin domain (FM: ﬂuoromyelin red) in live adult mouse RON. Highlighted square shown in insert as rendered
stack. e Myelin structure is protected from ischemic damage by 120min pre-treatment with QNZ-46, imaged via FM vital staining. f–h Ischemia evoked
myelin swelling (P= 0.000 in aCSF) is prevented by 120min QNZ-46 pre-treatment (P= 0.047 vs. aCSF). Scale= 10 μm
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test; P= 0.0001) and prevention of this effect by perfusion with QNZ-46 (P= 0.0007). j, k Mean data showing the changes in G-ratio under these
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(right) the mean FM intensity decline evoked by OGD (P= 0.00027), which is prevented by MK801 (P= 0.00062). Bar a, b, e, f= 1 μm; d= 5 μm; c, l=
100 nm
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to myelin axon proﬁles, was low in gray matter regions, and co-
localized with FM (Fig. 6b, c). Following i.p. injection (20 mg/kg
in 50/50 DMSO/β-cyclodextrin 240 min prior to the killing, based
on known CNS action of a similar compound27), vital QNZ-46
ﬂuorescence had a similar distribution in mouse brain slices to
that produced by bath loading (Fig. 6d, e), demonstrating brain
penetration and myelin retention (tissue was dissected into QNZ-
46 free aCSF for imaging).
QNZ-46 is an allosteric modulator of GluN2C/D-containing
NMDA GluRs with use-dependent features23,28. It is the most
selective inhibitor of GluN2C/D-containing GluR currently
identiﬁed with a >50-fold IC50 differential over GluN2A/B-
containing receptors. In silico modeling indicates drugability,
although with a high polar surface area (Supplementary Fig. 5c).
The myelin partitioning and trapping evident in Fig. 6a–e
suggests QNZ-46 may provide myelin protection following
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Fig. 6 QNZ-46 is absorbed by myelin. a QNZ-46 emission shows accumulation and retention in adult rat RON. b Confocal imaging of vital QNZ-46
ﬂuorescence (120min treatment) in adult corpus callosum (left) and the white matter–gray matter border (right). c Vital QNZ-46/FM co-staining of
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removal from the extracellular space. Indeed, 60 min pre-
treatment followed by 60 min of wash-out signiﬁcantly elevated
functional recovery in the adult rat RON (Fig. 6f). No similar
effect was found with the non-NMDA glutamate receptor blocker
NBQX, an anti-excitotoxic drug thought to act at the
oligodendrocyte cell body7 (Supplementary Fig. 6). Systemic i.p.
injection of QNZ-46 followed by 240 min recovery, dissection and
60 min bath perfusion with aCSF also increased compound action
potential (CAP) recovery in adult mouse RON from 6.8 ± 1.9% to
18.9 ± 5.6%, representing a >270% increase compared to vehicle-
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treated control (Fig. 6g). This effect was not potentiated by the
presence of QNZ-46 in the bath, suggesting that systemic QNZ-
46 pre-treatment and myelin trapping results in maximal
protection (Fig. 6g). The efﬁcacy of QNZ-46 trapped within
myelin may suggest drug interaction with an NMDA receptor site
within the lipid lamella/oligodendrocyte cell membrane. Alter-
natively, myelin may act as a reservoir that gradually releases
QNZ-46 to act at extra- or intra-cellular sites on the receptor. In
either case, our data suggest that incorporation of myelin-targeted
elements such as trans-stilbene may enhance the effectiveness of
myelin treatments generally.
Although crossing the blood−brain barrier and segregating
into myelin, systemic pre-treatment with QNZ-46 produced no
apparent behavioral effects or acute toxicity. A 120 min single
dose pre-treatment protocol was tested in a standard 60 min
transient middle cerebral artery occlusion (tMCAO) model of
stroke. Brain lesions assessed 24 h post-reperfusion in vehicle
treated wild-type mice included extensive damage to white matter
structures such as the external capsule and gray matter regions
such as the overlying motor cortex. Drug treatment greatly
reduced lesion volume and improved the performance in
behavioral tests compared to vehicle-treated controls (Fig. 7a±e).
External capsule axon integrity assessed via YFP expression in
Thy-1-YFP mice was lost within the lesion site in the vehicle
cohort, but was largely preserved in the QNZ-46 treated cohort
(Fig. 7g–j). Myelin integrity was protected to a similar extent
(Fig. 7g–j).
A second series of tMCAO data was generated with mice
perfusion ﬁxed after the 24 h recovery for ultrastructural analysis.
Lesion reduction following QNZ-46 pre-treatment was replicated
in these experiments (lesion volume vehicle= 119.4 ± 8.9 mm3,
QNZ-46= 38.9 ± 7.0 mm3; P < 0.0001). Neuronal somata, neuro-
pil, and white matter structure was well preserved in the external
capsule-motor cortex border region of the contralateral hemi-
sphere (Fig. 8c). Widespread cellular breakdown was apparent in
the comparable vehicle-treated ipsilateral region (Fig. 8d, e),
including necrotic cell death, neuropil degeneration, and
universal myelin destruction in both white matter tracts and
gray matter axons (Supplementary Fig. 7). In mice pre-treated
with QNZ-46, all cellular elements were relatively preserved
(Fig. 8f–h; Supplementary Fig. 7), with myelinated axons having
no signs of myelin splitting or bubbling. Largely uninjured
neuronal somata, neuropil, and glial somata were apparent
throughout the region, although astrocyte processes (some
containing glial ﬁlaments) were swollen and damaged (Fig. 8g,
white arrows). Quantitative assessment of somata injury (which
will include both neurons and glia since they cannot be reliably
distinguished post vehicle-treated injury) showed QNZ-46
protection in the ipsilateral hemisphere of both white matter
and gray matter areas, with no signiﬁcant difference in somata
damage between contra- and ipsilateral sides in white matter
(Fig. 8i). Myelin expansion (G-ratio, not measured in ipsilateral
white matter due to the extent of damage) was not present in the
ipsilateral white matter of QNZ-46-treated mice. It is apparent
from these in vivo experiments that a single dose pre-treatment
with QNZ-46 protected both gray matter and white matter
structures to deliver a high level of structural and functional
neuroprotection.
Discussion
The results highlight the signiﬁcance of vesicular glutamate
release from axons and demonstrate the involvement of this
phenomenon in ischemia-evoked myelin damage. Earlier reports
have documented reverse glutamate release under ischemic con-
ditions in the CA1 region of the neonatal hippocampus9, adult
spinal cord10, and mouse optic nerve11. To our knowledge, the
current report is the ﬁrst to directly measure extracellular gluta-
mate in white matter and while glutamate transport was found to
be signiﬁcant for homeostatic regulation of the neurotransmitter,
we found no evidence for signiﬁcant ischemic release via this
mechanism. Ischemic glutamate release pathways in the white
matter of the brain are likely to differ from those operating in
gray matter areas such as the hippocampus CA1, while earlier
white matter studies have generally examined secondary effects of
reverse glutamate transport block and this may account for the
discrepancy between earlier ﬁndings and the current results.
Approximately 95% of clinical strokes involve white matter,
which accounts for ~49% of stroke total mean infarct volume29.
Stroke in the territory of penetrating arteries preferentially target
white matter and accounts for ~25% of stroke cases, representing
the second leading cause of dementia3,30. White matter stroke
features rapid myelin damage31 and remyelination failure in
white matter lesions signiﬁcantly contributes to functional
loss3,30. The mechanisms underlying myelin injury in these acute
ischemic lesions have high clinical relevance and may share
common features with other forms of myelin damage, for
example those operating in multiple sclerosis and CNS
trauma32,33. We have shown that acute ischemic myelin injury
results from vesicular glutamate release from axons, leading to
cytotoxic over-activation of GluN2C/D-containing myelinic
NMDA GluRs preventable by the selective negative allosteric
modulator QNZ-46 (Supplementary Fig. 8). QNZ-46 has high
selectivity for GluN2C/D-containing GluRs, shows novel myelin
accumulation and retention, is brain accessible, and has the basic
features of a clinically useful drug, suggesting outstanding clinical
potential against excitotoxic myelin injury. QNZ-46 exhibits
persistent CNS protection, elevating injury tolerance after the
drug is removed from the extracellular space, and has clinical
potential for treatment of prevalent neurological disorders
involving myelin damage in particular in patients at risk of
ischemic injuries such as stroke.
While the neuroprotective effect of broad-spectrum NMDA
GluR blockers is well established, these drugs have failed to
translate into clinical practice. The reasons for this are complex
and involve unacceptable side effects and the short therapeutic
window that follows stroke onset. This second problem may be
insurmountable; the FAST-MAG trial achieved paramedic
delivery of the NMDA receptor blocker Mg2+ within 45 min of
stroke symptom onset but failed to improve outcomes34. Negative
allosteric modulators such as QNZ-46 exhibit use-dependent
block predisposing them to target pathological over-activation of
Fig. 7 A single QNZ-46 pre-treatment produces high levels of white matter and gray matter neuro-protection. a–c Brain lesion volume 24 h post-tMCAO.
d–f Functional recovery prior to the killing. Drug treatment signiﬁcantly improved the outcome in all measures. ANOVA with Holm−Šídák post test. P
values: b ***0.0000; c **0.000; e **0.004; f *0.011. Mann−Whitney test; d *<0.05. g–j YFP expression (green) and luxol fast-blue/cresyl violet (blue/
purple: myelin) in Thy-1-YFP mice. g YFP(+) axons project within the external capsule which is extensively myelinated in contralateral (Contra) and
ipsilateral (Ipsi) hemispheres in sham-operated mice. Higher power micrographs are shown at the bottom. hMice treated with vehicle show disruption and
loss of axonal YFP that extends to both hemispheres and loss of myelin within the ipsilateral white matter. i Drug-treated mice retain YFP(+) axons and
myelin staining in both hemispheres. j Myelin stain density is signiﬁcantly reduced in the vehicle-treated group (***0.0002), and preserved by QNZ-46
pre-treatment (**0.005). Scale bars= 100 μm
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receptors over normal physiological receptor function23,24. The
physiological functions of oligodendrocyte NMDA GluRs
includes regulation of GLUT-1 expression22 and axo-glial mye-
lin35. Constitutive targeted oblation of the obligatory Nr1 subunit
in oligodendrocytes leads to a switch in the mechanism regulating
myelination and a downregulation of GLUT-1 that is associated
with gradual structural compromise; these effects may be avoided
by this class of drug. In the adult CNS, GluN2C/D subunits are
primarily incorporated into extra-synaptic NMDA receptors36–38,
and are expressed at lower levels in gray matter regions than are
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other NMDA GluR subunits39,40, two additional factors that will
limit the side-effects of drug treatment. Stroke incidence is well
correlated with age, prior transient ischemic attack, hypertension,
and prior stroke41. Our ﬁndings suggest that prophylactic treat-
ment in patients at risk of stroke may offer an alternative strategy
for clinical intervention that avoids the therapeutic window. The
extent of the structural and functional neuroprotection offered by
QNZ-46 is surprising; in particular the effect in gray matter where
neuron somata and neuropil were protected against ischemic
injury in vivo. Targeting of extra-synaptic NMDA receptors has
shown promise for a wide range of neurological conditions
including dementia42, and QNZ-46 may protect gray matter in a
similar fashion. The combined protective effect in both categories
of CNS tissue adds to the clinical potential of the drug.
Methods
Animals and reagents. All animal procedures conformed to local ethical stan-
dards and ARRIVE guidelines. UK home ofﬁce and Maltese national regulations
were followed as appropriate. For RON experiments, nerves were dissected from
juvenile (P8–12) or adult (P90–120) Wistar rats, adult (P80–110) PLP-GFP or C57
wild-type mice. Acute coronal vibratome-cut sections were cut in oxygenated, ice-
cold cutting solution (in mM): NaCl, 92; KCl, 2.5; NaH2PO4, 1.2; MgSO4, 2; CaCl2,
2; NaHCO3, 30; glucose, 25; Hepes, 20; Na Pyruvate, 3; Thiourea, 2; Na Ascorbate,
5; pH, 7.4. Experiments were performed in artiﬁcial cerebrospinal ﬂuid (aCSF),
composition (in mM): NaCl, 126; KCl, 3; NaH2PO4, 2; MgSO4, 2; CaCl2, 2;
NaHCO3, 26; glucose, 10; pH, 7.45, bubbled with 5% CO2/95% O2 and kept at 37 °
C. KCl (47 mM) was added to aCSF (NaCl replacement) for “High K+” experi-
ments. For zero-Ca2+ aCSF, CaCl2 was omitted, and 50 μM EGTA was added. For
zero-Na+ aCSF, Na+ was replaced with NMDG. Oxygen–glucose deprivation was
used as the model of ischemia for CAP and confocal imaging experiments: aCSF
was replaced by a glucose-free aCSF (+10 mM sucrose to maintain osmolality)
saturated with 95% N2/5% CO2. The chamber atmosphere was switched to 5%
CO2/95% N2 during OGD perfusion. Osmolarity of solutions was measured and
adjusted as required. NBQX was purchased from Tocris (UK), PPDA and QNZ-46
from either Tocris or Abcam (UK), baﬁlomycin from Viva Bioscience (UK); all
other reagents were from Sigma (UK) including carbenoxolone (CBX), 5-nitro-2-
(3-phenyl-propylamino)benzoic acid (NPPB), sulfasalazine (SAS) and threo-beta-
benzyloxyaspartate (TBOA).
In vivo treatment for in vitro recording. Adult C57 mice were injected i.p. with
200 µl of 50% DMSO solution containing 1 mM β-cyclodextrin +20 mg/kg QNZ-
46, or a vehicle control without the QNZ-46. Injections were performed blind by
animal house staff and mice were left for 240 min on a warming pad. Other than
mild sedation in both groups attributed to the DMSO, the animals showed no signs
of distress or aberrant behavior. RON or brain slices were collected as above, in
solutions that did not contain QNZ-46.
Electrophysiology. RON CAPs were evoked and recorded with glass electrodes
and the rectiﬁed area used to determine changes in conduction. CAPs were evoked
via square-wave constant current pulses (Iso stim A320, WPI), ampliﬁed (Cyber
Amp 320, Axon Instruments), subtracted from a parallel differential electrode,
ﬁltered (low pass: 800–10,000 Hz), digitized (1401 mini, Cambridge Electronic
Design) and displayed on a PC running Signal software (Cambridge Electronic
Design). Non-recoverable CAP loss from the RON indicates irreversible failure of
axon function. Glutamate microelectrode biosensors (Sarissa Biomedical, Coventry,
UK), ampliﬁed via a Duo-Stat ME-200+ potentiostat (Sycopel International,
London, UK), were used to record glutamate concentration. Signals were differ-
ential to a null electrode and both active and null electrodes were gradually inserted
into brain slice or RON, in the latter case through a small incision in the nerve
sheath. An Ag/AgCl reference electrode was introduced into the bath. Sensors were
calibrated in the chamber at the end of each experiment. Values from the null,
sensor, and sensor-minus-null outputs were recorded at 0.5 Hz and subsequently
converted into glutamate concentration (Supplementary Fig. 4). Recorded gluta-
mate was high following electrode placement, presumably due to localized tissue
damage (Supplementary Fig. 4), and declined to a low stable concentration over a
120–180 min (neonatal RON), 300–420 min (adult RON) or 180–240 min (slices)
rest period before experiments were initiated. Nerves may have been pre-treated
with 50 μM BAPTA-AM for zero-Ca2+ experiments (no difference was detected
and data were pooled). Corpus callosum glutamate sensor experiments were
conducted on 400 µm sections from adult Wistar rats, adult (P80–110) THY-1/YFP
(Line H), GFAP-GFP or C57 wild-type mice. Slices were gradually warmed to 37 °C
over ~60 min and rested for 120 min prior to use. Unless otherwise stated, pre-
parations were maintained in an oxygenated (1.5 l/min) interface perfusion
chamber (Harvard Apparatus Inc.) and continuously superfused (0.6–1 ml/min)
with aCSF. Due to the oxygen-sensitivity of the glutamate biosensors, chemical
anoxia (1 nM rotenone for neonates/25 µM antimycin-a for adults)+ aglycemia
was used as the model of ischemia for [glutamate]e recordings.
Two-photon confocal imaging. After deep isoﬂurane anesthesia and decapitation,
the brain was rapidly removed into chilled aCSF supplemented with 75 mM
sucrose and vibratome sectioned into coronal slices (400 μm thick) from the genu
of the corpus callosum through the caudal extent of the hippocampus. Immediately
after sectioning, slices were transferred to a Haas-type interface brain slice chamber
(Harvard Apparatus, South Natick, MA) and allowed to recover at room tem-
perature in aCSF for 60 min. Slices were transferred to a mini submerged chamber
(0.5 ml) with a coverglass bottom (Warner Instrument Corporation, Hamden, CT)
mounted on an upright BX50W1 Olympus Multiphoton microscope (Olympus,
Tokyo, Japan) and perfused with room temperature aCSF at 3.5 ml/min. Final
temperature control (37 ± 1 °C) was maintained using an in-line heater (Warner
Instrument Corporation, Hamden, CT) equipped with a feedback thermistor
placed in the chamber and the temperature raised gradually over 60 min. The
multiphoton system housed Keplerian beam expanders with IR introduction light
paths. A mode-locked MaiTai HP DeepSee laser system (Spectra-Physics) with a
tuneable Ti: sapphire oscillator (690–1040 nm) was used as the excitation light
source (pulse width < 100 fs; pulse repetition rate 80 Mhz) and controlled through
an acousto-optical-modulator. The Group Velocity Dispersion was electronically
compensated by a prism-coupled pre-chirper and the beam diameter adjusted by a
Keplar telescope. Image acquisition was performed using the Olympus FluoView
software.
Vesicular imaging was conducted on brain slices from transgenic animals using
FM4-64. Corpus callosum slices were initially superfused with aCSF+ 10 µM FM4-
64 for 10 min. Slices were then subjected to a 50 mMK+ aCSF+ 10 µM FM4-64 for
5 min, and subsequently returned to aCSF+ 10 µM FM4-64 for a further 20 min.
Next, slices were washed in aCSF (without FM4-64) for 15 min and a suitable
region of the corpus callosum was identiﬁed. Finally, slices were exposed to 50
mMK+ aCSF for 10 min (or ischemia for 30 min) to promote vesicular fusion/
FM4-64 unloading. Images were acquired every 10 s following laser excitation at
890 nm and collected using standard red and green ﬁlter settings. Mean pixel
intensity within YFP(+) axons or GFP(+) astrocytes was determined using
Olympus FluoView software, with the regions of interest determined by the green
proﬁle of axons/glia. Fluorescent emission scans during excitation at 405 nm were
conducted using 10 nm bin width and the lambda-scan function, with 10 mM
QNZ-46 in DMSO diluted 50:50 in immersion oil.
Fig. 8 Structural protection following systemic QNZ-46 pre-treatment. a, b Brain lesions in vehicle- and QNZ-46-treated mice subject to the standard
MCAO protocol. Boxed areas (external capsule-motor cortex border) were examined via TEM. c Cortical neuronal somata (nuclei indicated by short
arrows), neuropil (arrow heads), and myelinated axons (long arrows) in contralateral QNZ-46-treated mice appeared normal with no unusual features. d, e
Ipsilateral vehicle-treated external capsule-motor cortex border showed wide-scale cellular destruction and loss of structure including disrupted myelinated
axon tracts (arrows d, e top left) and necrotic neuronal soma (arrow heads d, e bottom left). White matter glial cell soma and process were also necrotic
(e, top right, short arrow) and occasional distorted myelin proﬁles were apparent (e, top right, arrow). Cell processes in the neuropil were generally
disrupted with free-ﬂoating mitochondria present (e, bottom right). f–h Ipsilateral QNZ-46-treated external capsule-motor cortex border showed almost
normal structural features in both white matter and gray matter areas. Myelinated axon tracts showed no myelin damage (f, g top left, h arrows) and both
neuronal and glial soma (f, g top right, h short arrows) appeared largely intact. Glial processes were often swollen (g, bottom left and right white arrows)
and in many cases could be identiﬁed as astrocytic containing glial ﬁlaments (g, bottom right, white arrow). Neuronal, neuropil, and myelinated axon
proﬁles are shown at higher gain in the expanded boxed area in h (lower panel). i Cell viability was severely compromised (ANOVA with Holm−Šídák post
test; ***P= 0.0000) in ipsilateral vehicle-treated mice (where white matter and gray matter, neuron and glia could not always be distinguished and are
grouped together). QNZ-46 pre-treatment signiﬁcantly improved cell viability in both white matter and gray matter (***P= 0.0000 vs. untreated
ipsilateral injury), with no signiﬁcant difference between ipsi- and contralateral cells in white matter regions. j–k G-ratio was not signiﬁcantly different in
ipsi- and contralateral white matter axons in QNZ-46 pre-treated mice. Note axon disruption precluded the measurement of G-ratio in ipsilateral vehicle-
treated white matter
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Single-photon imaging. Live imaging of NMDA-receptor-mediated myelin injury:
PLP-GFAP RONs were exposed to FluoroMyelin Red (5%; 100 min, 5 °C in cutting
solution) with or without drug, prior to dye wash-out and mounting in a
temperature-controlled perfusion chamber (Warner Instruments, Hamden, CT,
USA). RONs were superfused at 2 ml/min with aCSF with or without drug and
imaged in a single plane on an inverted Nikon TE2000-U microscope. Imaging was
achieved via spinning disk confocal imaging (Crest-Optics, X-light) and collected
via MetaMorph software (Molecular Devices). FluoroMyelin Red and GFP was
consecutively imaged following excitation of both at 488 nm using a 650 ± 50 nm
BP ﬁlter (Thorlabs, Newton, New Jersey, USA) and a standard GFP ﬁlter set
(Chroma Technology Corporation, Bellows Falls, VT, USA), respectively. RONs
were imaged 20 min prior to switching to a 60-min period of OGD and then
switched back for 60 min of recovery. Myelin decompaction was assessed using
intensity line-plots drawn perpendicular to the longitudinal axis of individual
myelin sheaths using ImageJ (NIH). Pre-OGD myelin sheath width was not sig-
niﬁcantly different in control and treated preparations and the data were pooled.
Single-photon, laser scanning confocal images of QNZ-46 bath-loaded adult mouse
ON and 200 μm coronal brain sections (P90–120) Wistar rats, (P80–110) PLP-GFP
or C57 mice and brain sections from QNZ-46-injected mice, were collected using a
Leica TCS SP8 microscope, using loading protocol and settings for GFP and
FluoroMyelin Red comparable to those used for spinning disk above. QNZ-46 was
imaged following excitation at 405 nm using ﬁlter settings standard for DAPI
emission. Wide-ﬁeld QNZ-46 imaging was performed using an Olympus epi-
ﬂuorescence microscope and a standard DAPI ﬁlter set; emission was quantiﬁed
from the whole nerve section using ImageJ.
Measurement of myelinic vesicular-mediated Ca2+ increase: brain sections
were prepared from adult (p100-p160) CD1 WT mice and dye loaded at room
temperature (22 °C) for 2 h in the presence or absence of baﬁlomycin in
continuously bubbled aCSF (5% CO2/95% O2) containing 10 μM X-Rhod-1 AM
and 1 μM DiOC68. Subsequently, sections were maintained in DiOC6-containing
aCSF with or without baﬁlomycin until imaging. Dye-loaded sections were placed
in a perfusion chamber and continuously superfused at 1 ml/min with bubbled
aCSF or high-K aCSF (50 mMK+, see above). Single-photon laser scanning
confocal images of corpus callosum myelinated axons were collected using a Leica
TCS SP8 microscope at 37 °C. Excitation/emission wavelengths was 488/492–560
nm for DiOC6 and 561/585–655 nm for X-Rhod-1. Polygonal ROIs of DiOC6 and
X-Rhod-1 dual-loaded axons were selected to exclude adjacent X-Rhod-1-loaded
cell bodies. X-Rhod-1 intensity was normalized to the pre-high-K signal and data
from individual mice were averaged for a single n (1–3 slices per mouse).
Transient middle cerebral artery occlusion. Eleven male Thy1-YFP and 15 C57
wild-type mice weighing 25−30 g were analgesized with buprenorphine (0.03 mg/
kg b.w. i.p.) 2 h before surgery and subsequently anesthetized with isoﬂurane (3%
initial, 1.0–1.5% maintenance) and 60% NO in O2. Animals were maintained
normothermic (37 ± 0.5 °C) by means of a servo controlled heating blanket
(Harvard Apparatus, Holliston, MA) with rectal temperature monitoring. Pulse
oximetry (Spo2), heart rate, and respiratory rate were monitored continuously
(STARR Life Sciences Corp., Allison Park, PA), along with systemic blood pressure
via a Kent CODA® Standard tail-cuff blood pressure system (Kent Scientiﬁc
Corporation, Torrington, USA). A ﬁber-optic probe (VP10M200ST, Moor
Instruments Ltd, Axminster, UK) was afﬁxed to the skull over the middle cerebral
artery for measurement of regional cerebral blood ﬂow using a moorVMS-LDF
Laser Doppler System. Under microscope, the left common carotid, internal car-
otid, and external carotid arteries were exposed through a midline neck incision.
The proximal portions of the left common carotid and the external carotid arteries
were ligated and a 6–0 silicon-coated nylon suture (60SPRePK5-21910, Doccol
Corporation, Massachusetts, USA) introduced into the internal carotid artery to
occlude the middle cerebral artery at its origin. Mice were allowed to recover from
anesthesia in a warm recovery cage throughout the duration of occlusion. After 60
min, reperfusion was obtained by withdrawal of the suture. Middle cerebral artery
occlusion was conﬁrmed by a sudden drop in relative cerebral blood ﬂow to
approximately 85% less than baseline measurement. Animals were subsequently
administered buprenorphine for analgesia and placed in a recovery cage for 2 h
before returning to their home cages with free access to food and water. Plasma
glucose concentration was measured before tMCAO, 5 min and 24 h after reper-
fusion. Sham-treated animals received all surgical procedures but the ﬁlament was
not inserted into the MCA. For animals pretreated with either QNZ-46 or vehicle
(50:50;DMSO/β-cyclodextrin), the active drug or carrier was administered intra-
peritoneally 120 min before tMCAO.
Clinical evaluation. Body weight (g) was recorded prior to surgery and at 24 h for
sham-, vehicle- and drug-treated groups. While a slight weight increase was
observed in sham controls, experimental groups demonstrated weight loss after 24
h. Ischemia-induced weight loss was attenuated in drug-treated mice compared to
vehicle group, although this was not signiﬁcant (vehicle vs. drug-treated group:
5.30 ± 0.38 g vs. 4.58 ± 0.33 g).
Modiﬁed Bederson score. Neurological performance43 was assessed by two
independent and blinded investigators 24 h post tMCAO according to the
following scoring system: 0, no neurological deﬁcit; 1, forelimb ﬂexion; 2, decreased
resistance to lateral push; 3, unidirectional circling; 4, longitudinal spinning; 5, no
movement.
Corner test. The corner test detects abnormalities of sensory and motor function
including vibrissae, forelimb and hindlimb use, and postural motor function44. The
apparatus consisted of two cardboard boards each with a dimension of 30 × 20 × 1
cm3. The edges of the two boards were attached at a 30° angle with a small opening
along the joint to encourage entry into the corner. The mouse was made to enter
between the two boards facing the corner. As the animal progressed into the
corner, both sides of the vibrissae were stimulated together and the mouse reared
forward and upward, and then back to face the open end of the boards. The
direction towards which the mouse turned was recorded for a total of ten trials per
animal. Recordings were performed at baseline (prior to surgery) and again at 24 h
reperfusion.
Wire hanging test. Motor function was evaluated using a wire hanging test for
grip strength, balance, and endurance. This test is based on the latency of a mouse
to fall off a metal wire upon exhaustion. The apparatus consisted of a 2-mm-thick
metallic wire stretched between two poles held 50 cm above the ground, with a
pillow in between to prevent injury upon falling. The mouse’s hindlimbs were
covered with adhesive tape to prevent the animal from using all four paws. The
mouse was trained to suspend its body by holding on to the wire. Pre-training was
performed for 2 consecutive days before and on surgery day, prior to obtaining
baseline values. The mouse was suspended for short intervals (10–20 s) for several
trials and then returned to its cage. If the mouse fell before the end of the trial, it
was immediately returned and allowed to grasp the wire. Mice were only returned
to their home cage once training was completed. Experimental recordings were
taken at baseline (prior to surgery) and again at 24 h reperfusion. Suspension time
was measured for three trials per session with a maximum of 60 s per trial and a
30-s recovery period in between.
Infarct volume. Lesion volume was assessed 24 h post-MCAO following neuro-
logical assessment. Brains were removed, sectioned at 2 mm using a brain matrix
and incubated in 2% 2,3,5-triphenyltetrazolium chloride (TTC; Sigma-Aldrich) in
saline for 20 min at 37 °C. Four slices per mouse were imaged and processed for
infarct volume evaluation by blinded manual area tracing using digital imaging and
image analysis software (ImageJ). For each section, the unstained area was deﬁned
as the ischemic lesion while red-stained areas delineated viable tissue43. Direct
infarct volume was calculated by linear trapezoidal extrapolation (Cavalieri prin-
ciple); for each brain sample, volume of infarction was calculated by integrating the
area of damage at each stereotactic level and the slice thickness. An indirect/
corrected infarct volume was then calculated to compensate for the space-
occupying effect of brain edema. For each brain, an edema index was calculated by
dividing the sum of ipsilateral hemisphere volumes by the sum of contralateral
hemisphere volumes. The actual infarct volume adjusted for edema was then
determined by dividing the direct infarct volume by the edema index45.
Tissue processing and histological assessment. Thy-1-YFP mice subject to
sham-, vehicle- and drug-treated tMCAO were killed (ketamine/xylazine), trans-
cardially perfused (4% paraformaldehyde in PBS) and the brains were removed,
post-ﬁxed (24 h at 4 oC), cryopreserved (30% sucrose for 72 h at 4oC), embedded
(low-melting point agarose, Sigma-Aldrich, A0576), and chilled. Free-ﬂoating 20
µm coronal sections (compresstome VF-300, Precisionary Instruments Inc., San
Jose, California) were mounted onto gelatin-coated slides and YFP-imaged (EVOS
Auto FL, ThermoFischer Scientiﬁc) using the appropriate green (496/518) ﬁlter set.
The sections were immediately subsequently stained with 0.1% luxolfast blue (LFB,
Solvent Blue 38, Sigma-Aldrich)/0.25% cresyl violet (Sigma-Aldrich) and myelin-
imaged bright ﬁeld. The mean optical density (OD) of the LFB stain was used as a
measure of myelin integrity46. For each section, two ×20 and ﬁve ×60 non-
overlapping images from homologous ipsilateral and contralateral external capsule
were acquired and processed for OD using ImageJ software. OD calibration was
carried out such that pixel values, usually in gray level units, were in OD. Each
image was converted to 8-bit and the ROI was outlined manually. Any incidental
border region of the cortex was excluded from analysis. OD was measured from
ipsilateral and corresponding contralateral hemispheres and expressed as a ratio.
Electron microcopy. For brain sections: 24 h following the standard tMCAO
protocol mice were anesthetized and transcardially perfused for 5 min with cold 4%
PFA in 0.1 M Sørensen’s solution. The brain was then removed, sectioned at 2 mm
using a brain matrix and incubated in 2% TTC for 20 min and assessed for lesion
volume as above. Sections were then immersion-ﬁxed in 2.5% gluteraldehyde/0.1 M
Sørensen’s overnight and stored in Sørensen’s solution. The external capsule-motor
cortex border region from both hemispheres was excised prior to post-ﬁxation (1%
osmium tetroxide), serially dehydration and epoxy inﬁltration. Ultrathin coronal
sections (50–70 nm) were counterstained with uranyl acetate and lead citrate prior
to blind examination using a Jeol 100CX electron microscope. Micrographs were
analyzed for axon G-ratio by hand tracing (ImageJ, NIH) the external and internal
myelin proﬁle of all X-S axons within a micrograph and converting the area to
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idealized circles. Somata viability was assessed using a basic scoring system where
one point was awarded for each of: (a) an intact cell membrane; (b) the presence of
undamaged organelles such as mitochondria; (c) a normal nuclear morphology;
and (d) the presence of clear cytoplasm. The external capsule-motor cortex border
region of three vehicle-treated and three QNZ-46-treated mice were analyzed.
For RON: following either 30 min OGD (for long-sectioning: L-S) or 60 min
OGD+ 60 min recovery (for cross-sectioning: X-S), adult mouse nerves were
immersion-ﬁxed in 4% PFA in Sørensen’s for 5 min followed by 2.5%
gluteraldehyde/0.1 M Sørensen’s overnight and storage in Sørensen’s. A minimum
of four grid-sections in each of a minimum of three nerves were analyzed blind by
hand including the tracing of axons and myelin proﬁles (X-S), axoplasmic vesicle
counting (L-S) and focal myelin damage (L-S). G-ratio in X-S was calculated as
above; vesicle counting was performed in L-S to allow vesicles to be distinguished
from microtubules. Focal myelin injury was scored: 0= normal compact myelin; 1
= one layer of myelin splitting; 2=myelin bubbling involving multiple lamella; 3
= complete myelin breakdown.
Statistics. Data are mean ± SEM, signiﬁcance determined by ttest or ANOVA with
Holm−Šídák post hoc test as appropriate; Mann−Whitney U test was performed
for nonparametric variables (Modiﬁed Bederson Score). CAP and biosensor
recordings were stable over long periods of control recording and glutamate
receptor antagonists had no effect under control conditions (Supplementary Fig. 6).
For long periods of drug pre-treatment, control experiments were performed with
the identical protocols to allow direct comparison. *P= <0.05 (rounded three
decimal places), **P= <0.01 (rounded three decimal places), ***P= <0.001
(rounded four decimal places). Sample sizes for experimental groups are based on
power calculations using established variability. Data from all completed experi-
ments are included and no outliers were excluded. Two animals subjected to
tMCAO died post-operatively and were not counted. Sham and test tMCAO trials
were alternated and the experimenters were blinded to the contents of the injection;
the micrographs generated from these experiments were analyzed blind (REF) and
only unblinded once analysis was complete. All test experiments were intercalated
with the relevant controls and where possible trials were conducted blind,
including all in vivo treatments.
Data availability. All relevant data are available from the authors upon request.
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